British Columbia Adds Three Anti-Clotting Biosimilars To PharmaCare
The Enoxaparin Biosimilars Include Redesca, Noromby And Inclunox
British Columbia has added three new biosimilar versions of the anti-clotting drug enoxaparin to PharmaCare, including Redesca, Noromby and Inclunox. The move comes after the Canadian province recently included additional biosimilars in its switching program.
You may also be interested in...
Patients taking Humalog and NovoRapid will have six months to switch to their biosimilar equivalents after British Columbia added the rapid-acting insulins to its biosimilar switching policy.
Kelix bio has announced two deals to expand its presence in Africa. The company is set to acquire 14 oncology injectable products from Germany-based Vitane. Furthermore, Kelix has acquired Pharmaceutical Institute, a pharmaceutical company established in Rabat, to enter Morocco. The pan-African company has also invested in Malta.
Cipla has partnered with mAbxience to supply oncology and respiratory-related biosimilars on the WHO model list of essential medicines to South Africa.